Abstract
Biofluid biomarkers to track neurodegenerative diseases in vitam are urgently needed. Recent studies show that large-scale proteomic analyses based on the proximity extension assay may reveal novel biomarkers reflecting disease pathophysiology. Such biomarkers will likely express their maximal clinical value when used in combination with pathology-specific biomarkers.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
